Compare TRMK & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | TMDX |
|---|---|---|
| Founded | 1889 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1994 | 2019 |
| Metric | TRMK | TMDX |
|---|---|---|
| Price | $46.18 | $92.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $44.50 | ★ $148.22 |
| AVG Volume (30 Days) | 317.9K | ★ 895.0K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | 1.93 | ★ 382.18 |
| EPS | ★ 2.03 | 0.61 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $9.82 | $24.25 |
| Revenue Next Year | $4.86 | $18.75 |
| P/E Ratio | ★ $22.71 | $153.44 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $36.33 | $60.11 |
| 52 Week High | $49.00 | $156.00 |
| Indicator | TRMK | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 60.53 |
| Support Level | $45.10 | $66.64 |
| Resistance Level | $46.34 | $120.91 |
| Average True Range (ATR) | 0.68 | 3.48 |
| MACD | -0.26 | 0.23 |
| Stochastic Oscillator | 18.48 | 75.24 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.